Stoke Therapeutics (NASDAQ:STOK) Upgraded at Cantor Fitzgerald
Cantor Fitzgerald upgraded shares of Stoke Therapeutics (NASDAQ:STOK – Free Report) to a strong-buy rating in a research note released on Wednesday morning,Zacks.com reports. Cantor Fitzgerald also issued estimates for Stoke Therapeutics’ FY2025 earnings at $0.03 EPS. Other equities analysts also recently issued reports about the company. Chardan Capital reaffirmed a “buy” rating and issued […]
Cantor Fitzgerald upgraded shares of Stoke Therapeutics (NASDAQ:STOK – Free Report) to a strong-buy rating in a research note released on Wednesday morning,Zacks.com reports. Cantor Fitzgerald also issued estimates for Stoke Therapeutics’ FY2025 earnings at $0.03 EPS. Other equities analysts also recently issued reports about the company. Chardan Capital reaffirmed a “buy” rating and issued […]
